Výsledky vyhledávání - "Deborah Weng Cherng"

Akademický článek

Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk.

Autor: Pablo Tebas, William Keith Henry, Roy Matining, Deborah Weng-Cherng, John Schmitz, Hernan Valdez, Nasreen Jahed, Laurie Myers, William G Powderly, David Katzenstein

Publikováno v: PLoS ONE, Vol 3, Iss 4, p e2021 (2008)

Concern about costs and antiretroviral therapy (ART)-associated toxicities led to the consideration of CD4 driven strategies for the management of HIV. That approach was evaluated in the SMART trial that reported an unexpected increase of cardiovascu

Externí odkaz: https://doaj.org/article/984dca58dd81436b800c376ea484e5f6

Zobrazit plný text záznamu

Safety, Tolerability, and Pharmacokinetic Effects of Thalidomide in Patients Infected with Human Immunodeficiency Virus: AIDS Clinical Trials Group 267

Autor: Dawn Bell, David A. Wohl, Francesca T. Aweeka, Roger J. Pomerantz, Lawrence Fox, David Simpson, M.K. Holohan, Gilla Kaplan, Deborah Weng Cherng, John Spritzler, Hedy Teppler, John L. Schmitz, Wayne Malcolm Robinson, Steven Thomas

Publikováno v: The Journal of Infectious Diseases. 185:1359-1363

Thalidomide is used to treat human immunodeficiency virus (HIV)-associated conditions, including aphthous ulcers and wasting syndrome. The safety, tolerability, and pharmacokinetics of a formulation of thalidomide with improved bioavailability in HIV

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f4b07ea0dfdc0b2572f2cd938b2929b
https://doi.org/10.1086/340133

Zobrazit plný text záznamu

Metabolic and Immune Activation Effects of Treatment Interruption in Chronic HIV-1 Infection: Implications for Cardiovascular Risk

Autor: Roy M. Matining, David Katzenstein, William Keith Henry, Laurie Myers, Hernan Valdez, Pablo Tebas, John L. Schmitz, Deborah Weng-Cherng, William G. Powderly, Nasreen C. Jahed

Publikováno v: PLoS ONE
PLoS ONE, Vol 3, Iss 4, p e2021 (2008)

Background Concern about costs and antiretroviral therapy (ART)-associated toxicities led to the consideration of CD4 driven strategies for the management of HIV. That approach was evaluated in the SMART trial that reported an unexpected increase of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d1356a9e2623269cf84588fe4af470b
http://europepmc.org/articles/PMC2292263

Zobrazit plný text záznamu

The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328

Autor: Becky L. White, John L. Fahey, Richard C. Reichman, J. Michael Kilby, Richard B. Pollard, Pablo Tebas, Ronald T. Mitsuyasu, Anne Marie Duliege, Alan L. Landay, Alejo Erice, Rebecca Gelman, R. Pat Bucy, Carol Dukes Hamilton, Michael M. Lederman, Deborah Weng Cherng, Juan J.L. Lertora

Publikováno v: Archives of internal medicine. 167(6)

BACKGROUND: Interleukin 2 (IL-2) administration increases CD4 counts in persons with higher counts. This study investigated persons with moderately advanced human immunodeficiency virus infection receiving highly active antiretroviral therapy (HAART)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8ce9b21f103d36ac4ca9a5f91f8ac8b
https://pubmed.ncbi.nlm.nih.gov/17954814

Zobrazit plný text záznamu

A pilot study evaluating time to CD4 T-cell count350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102

Autor: Keith Henry, John L. Schmitz, Michelle Blanchard Vargas, Deborah Weng Cherng, Hernan Valdez, David Katzenstein, Pablo Tebas, Jeffrey M. Jacobson, Nasreen C. Jahed, Mark A. Winters, William G. Powderly, Laurie Myers

Publikováno v: Journal of acquired immune deficiency syndromes (1999). 42(2)

Although an intermittent antiviral treatment (ART) strategy may limit long-term toxicity and cost, there is concern about the risk for virologic failure, selection of drug resistance mutations, and disease progression. By boosting CD4 T-cell counts,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80c627b550f24455e8c203b39bc220f4
https://pubmed.ncbi.nlm.nih.gov/16760795

Zobrazit plný text záznamu

Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248)

Autor: Richard B. Pollard, Hedy Teppler, Kathleen Squires, Donna Mildvan, Fred T. Valentine, Laura F. Mahon, Michael M. Lederman, Barbara Schock, Charles J. Gonzalez, Deborah Weng Cherng, Rebecca Gelman, Mary A. Vogler, Roger J. Pomerantz, Ian Frank

Publikováno v: Journal of acquired immune deficiency syndromes (1999). 36(1)

Context: Approaches to preserve or enhance immune function in HIV-1 infection are needed. Objectives: To examine the ability of daily low-dose interleukin-2 (IL-2) in combination with antiretroviral therapy to preserve circulating CD4 T-cell counts,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d65ce31c32678c3763558a145928b796
https://pubmed.ncbi.nlm.nih.gov/15097300

Zobrazit plný text záznamu

Evaluation of HIV-1 Immunogen, an Immunologic Modifier, Administered to Patients Infected With HIV Having 300 to 549 × 106/L CD4 Cell CountsA Randomized Controlled Trial

Autor: Henry W. Murray, James O. Kahn, Stephen W. Lagakos, Kenneth H. Mayer, Deborah Weng Cherng

Publikováno v: JAMA. 284:2193

ContextDespite enormous improvements achieved through the use of antiretroviral therapies (ARTs), the risk for eventual human immunodeficiency virus (HIV) disease progression remains high. Agents that enhance the immunologic mechanism for viral recog

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::88d3ba5a6a5ae2eeff6526547494b859
https://doi.org/10.1001/jama.284.17.2193

Zobrazit plný text záznamu

Efficacy and Safety of Adefovir Dipivoxil With Antiretroviral TherapyA Randomized Controlled Trial

Autor: Steven G. Deeks, Edmund Ng, Julie M. Cherrington, Gildon N. Beall, Deborah Weng Cherng, Richard S. Cooper, Dion F. Coakley, Nesli Basgoz, John J. Toole, Michael I. Miller, Michael Wulfsohn, James O. Kahn, David J. Hardy, Dean L. Winslow, Stephen W. Lagakos, Robert L. Murphy

Publikováno v: JAMA. 282:2305

ContextAdefovir dipivoxil is a nucleotide analog that has demonstrated effective antiretroviral activity against human immunodeficiency virus (HIV) with once-daily administration.ObjectiveTo determine if adefovir confers antiretroviral or immunologic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::de7f4f745ea259670f1384c5561dd393
https://doi.org/10.1001/jama.282.24.2305

Zobrazit plný text záznamu

Akademický článek

Daily Low-Dose Subcutaneous Interleukin-2 Added To Single- or Dual-Nucleoside Therapy in HIV Infection Does Not Protect Against CD4⁺ T-Cell Decline or Improve Other Indices of Immune Function: Results of a Randomized Controlled Clinical Trial (ACTG 248).

Autor: Vogler, Mary A., Teppler, Hedy, Gelman, Rebecca, Valentine, Fred, Lederman, Michael M., Pomerantz, Roger J., Pollard, Richard B., Deborah Weng Cherng, Gonzalez, Charles J., Squires, Kathleen E., Frank, Ian, Mildvan, Donna, Mahon, Laura F., Schock, Barbara

Publikováno v: JAIDS: Journal of Acquired Immune Deficiency Syndromes; 5/1/2004, Vol. 36 Issue 1, p576-587, 12p, 4 Charts, 5 Graphs

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání